Medpace closed at $568.36 in the latest trading day, marking a 1.45% increase. This was higher than the S&P 500’s rise of 0.88%, the Dow’s 0.38%, and the Nasdaq’s 1.31%.
Despite this, Medpace’s stock has seen a 4.43% decline over the past month, while the Medical sector grew by 1.2% and the S&P 500 improved by 2.48%. The firm is anticipating its upcoming earnings report, forecasting an EPS of $4.18, which is a growth of 13.9% from the previous year. Revenue is estimated at $681.17 million, a 26.94% increase year-on-year.
Annual forecasts predict earnings of $14.79 per share and $2.5 billion in revenue, marking increases of 17.1% and 18.68%, respectively. Analyst revisions in estimates may suggest positive perceptions of Medpace’s business prospects.
Notably, Medpace has a Zacks Rank of #2 (Buy), based on estimates changes that often influence share prices. The Forward P/E ratio is 37.88, higher than the industry average of 15.44, while the PEG ratio is 2.11 compared to the industry’s 1.62.
The Medical Services sector ranks 151 out of over 250 in the Zacks Industry Rank. Investors are encouraged to use resources like Zacks.com to stay informed.
The recent 4.43% dip in an otherwise strong year for Medpace presents an interesting entry point ahead of its earnings report. We see high expectations for both revenue and profit growth, which suggests implied volatility in its options will likely be elevated. Given this, buying the stock outright at these levels carries significant risk if the company fails to deliver a substantial beat on its upcoming announcement.
For those bullish on the report, we think using call options for January or February 2026 could be a prudent strategy. This allows for participation in a potential post-earnings rally while defining risk to the premium paid. Looking back, Medpace has established a consistent pattern of surpassing earnings estimates, beating them in each of the last four quarters reported through late 2025.
However, we must consider the stock’s high valuation, with a Forward P/E ratio more than double its industry average. This premium valuation suggests that any disappointment in earnings or forward guidance could lead to a sharp sell-off. Traders anticipating this could consider buying put options as a direct way to profit from a potential downturn in the coming weeks.
The broader economic picture also adds a layer of caution. While the global CRO market is estimated to have grown by over 11% in 2025, the higher interest rate environment we’ve navigated since 2024 has tightened funding for smaller biotech firms. This could create headwinds for future contract growth, a risk that the current stock price may not fully reflect.
A strategy that accounts for a large move in either direction, such as a long straddle, could be appropriate for the coming weeks. This involves buying both a call and a put, profiting from a significant price swing regardless of direction. With broader market volatility, as measured by the VIX, hovering around 17 recently, the cost of such a strategy may be reasonable for capturing a major post-earnings reaction.
